本文選題：鼻咽癌　切入點(diǎn)：重組人血管內(nèi)皮抑制素　出處：《中國(guó)現(xiàn)代醫(yī)學(xué)雜志》2017年03期

【摘要】：目的分析重組人血管內(nèi)皮抑制素聯(lián)合同步放化療對(duì)鼻咽癌患者預(yù)后和腫瘤惡性程度的影響。方法選取2012年11月-2015年1月在該院接受治療的78例鼻咽癌患者作為研究對(duì)象,根據(jù)治療方式分為接受重組人血管內(nèi)皮抑制素聯(lián)合同步放化療的觀察組36例,接受單純同步放化療的對(duì)照組42例。對(duì)比兩組患者治療后鼻咽癌預(yù)后相關(guān)因子蛋白表達(dá)量、血清生長(zhǎng)因子水平、血清病情相關(guān)因子水平差異。結(jié)果觀察組患者治療后鼻咽癌標(biāo)本中乙酰肝素酶、蛋白激酶CK2β、缺氧誘導(dǎo)因子-1α、潛伏膜蛋白蛋白表達(dá)量均低于對(duì)照組(P0.05);觀察組患者治療后血清轉(zhuǎn)化生長(zhǎng)因子β1、血小板源性生長(zhǎng)因子-β、表皮生長(zhǎng)因子、表皮生長(zhǎng)因子受體、血管內(nèi)皮生長(zhǎng)因子值均低于對(duì)照組(P0.05);觀察組患者治療后血清巨噬細(xì)胞炎性蛋白-3α、α-羥基丁酸脫氫酶、細(xì)胞角蛋白19片段、胸苷激酶-1、Ⅲ型前膠原、層粘連蛋白值均低于對(duì)照組(P0.05)。結(jié)論鼻咽癌患者接受重組人血管內(nèi)皮抑制素聯(lián)合同步放化療,可以降低腫瘤惡性程度并優(yōu)化治療預(yù)后,具有積極的臨床意義。
[Abstract]:Objective to analyze the effects of recombinant human vascular endothelial inhibin combined with concurrent radiotherapy and chemotherapy on the prognosis and malignancy of nasopharyngeal carcinoma (NPC). Methods 78 patients with nasopharyngeal carcinoma who were treated in our hospital from November 2012 to January 2015 were selected as the study subjects. According to the treatment methods, 36 patients were treated with recombinant human vascular endothelin combined with concurrent radiotherapy and chemotherapy, and 42 patients were treated with single concurrent radiotherapy and chemotherapy. The expression levels of prognostic factors related to the prognosis of nasopharyngeal carcinoma were compared between the two groups. Results heparinase was found in patients with nasopharyngeal carcinoma after treatment. The expression of protein kinase CK2 尾, hypoxia inducible factor -1 偽 and latent membrane protein was lower than that of control group (P 0.05), and the levels of transforming growth factor 尾 1, platelet-derived growth factor- 尾, epidermal growth factor and epidermal growth factor receptor were significantly lower in the observation group after treatment. Serum macrophage inflammatory protein -3 偽, 偽 -hydroxybutyrate dehydrogenase, cytokeratin 19 fragment, thymidine kinase -1, type 鈪，

本文編號(hào)：1669133